Editing CPT-11 (Irinotecan)

{{TreatmentInfo
|drug_name=CPT-11 (Irinotecan)
|FDA_approval=Approved for the treatment of colon cancer; under investigation for recurrent glioma
|used_for=Recurrent Glioblastoma Multiforme (GBM) and other malignant gliomas
|clinical_trial_phase=Phase I/II trials in combination with other therapies
|common_side_effects=Hematologic, gastrointestinal, and hepatic toxicities noted; acceptable safety profile in combination regimens
|OS_without=Not directly specified; historical control data needed for comprehensive comparison
|OS_with=Increases observed in specific combination trials, such as Irinotecan with Bevacizumab
|PFS_without=Variable across studies
|PFS_with=Enhancements in progression-free survival noted in combination therapies, ranging from improvement in median progression-free survival times to higher 6-month survival rates
|usefulness_rating=Under investigation; early results promising, especially in combination therapies
|usefulness_explanation=The combination of CPT-11 with agents like Bevacizumab and Temozolomide has shown potential in treating recurrent malignant gliomas, suggesting a meaningful clinical benefit in this challenging patient population.
|toxicity_level=3
|toxicity_explanation=While showing promise in efficacy, the combination treatments involving CPT-11 have been associated with manageable but significant toxicities, including hematologic, gastrointestinal, and hepatic adverse events.
|book_text=Investigations into CPT-11 for recurrent glioma, particularly in combination with other chemotherapy agents and targeted therapies, have demonstrated potential improvements in patient outcomes. These early phase trials underscore the importance of further research to optimize dosing, manage toxicities, and ultimately improve survival and quality of life for patients with recurrent malignant gliomas.
|category=Other chemotherapy agents at recurrence
}}